In a study by Hamann et al,[6] carriers of BRCA1/2 mutations (n = 65) were more likely to experience symptoms of PTSD (measured via semistructured diagnostic interviews) resulting from the screening experience, compared to noncarriers, 3 to 6 months after being informed about BRCA1/2 status. The gene discussed is BRCA1; the disease is post-traumatic stress disorder.